4D Molecular Therapeutics, Inc. (FDMT) Financial Ratios
9 years of historical data (2017–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
1.14
↓-37% vs avg
5yr avg: 1.81
30Y Low0.6·High4.3
ROE
↓
-27.6%
↓+18% vs avg
5yr avg: -33.6%
30Y Low-62%·High-25%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
FDMT Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
4D Molecular Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $519M | $434M | $300M | $793M | $719M | $608M | $1.1B | — | — | — |
| Enterprise Value | $480M | $396M | $176M | $558M | $682M | $472M | $829M | — | — | — |
| P/E Ratio → | -4.10 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 6.09 | 5.10 | 8120.72 | 38.26 | 229.63 | 33.73 | 81.25 | — | — | — |
| P/B Ratio | 1.14 | 0.86 | 0.59 | 2.58 | 3.11 | 1.91 | 4.31 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
FDMT EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 4.64 | 4749.64 | 26.94 | 218.05 | 26.16 | 60.92 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — |
FDMT Profitability
Margins and return-on-capital ratios measuring operating efficiency
4D Molecular Therapeutics, Inc. earns an operating margin of -187.2%. Operating margins have expanded from -544.6% to -187.2% over the past 3 years, signaling improving operational efficiency. A negative ROE of -27.6% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 91.1% | 91.1% | 100.0% | -368.5% | -2464.8% | -240.2% | -289.6% | -454.2% | -30.0% | -134.4% |
| Operating Margin | -187.2% | -187.2% | -507678.4% | -544.6% | -3516.5% | -395.5% | -416.3% | -726.7% | -73.6% | -194.7% |
| Net Profit Margin | -164.4% | -164.4% | -434778.4% | -486.6% | -3435.4% | -395.4% | -416.5% | -705.8% | -67.6% | -193.8% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -27.6% | -27.6% | -39.3% | -37.4% | -39.1% | -24.8% | -61.8% | — | — | — |
| ROA | -24.9% | -24.9% | -35.7% | -33.5% | -34.9% | -22.2% | -32.7% | -63.5% | -15.4% | -41.1% |
| ROIC | -28.1% | -28.1% | -61.4% | -63.1% | -43.7% | -66.0% | — | — | — | — |
| ROCE | -30.3% | -30.3% | -44.1% | -39.8% | -37.7% | -23.4% | -35.8% | -75.7% | -18.9% | -52.6% |
FDMT Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $60M exceeds total debt of $21M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.04 | 0.04 | 0.05 | 0.05 | 0.07 | 0.05 | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.08 | -0.24 | -0.76 | -0.16 | -0.43 | -1.08 | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | -3.11 |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — |
Net cash position: cash ($60M) exceeds total debt ($21M)
FDMT Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
4D Molecular Therapeutics, Inc.'s current ratio of 9.39x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 15.65x to 9.39x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 9.39 | 9.39 | 14.92 | 15.65 | 14.02 | 15.69 | 16.88 | 4.05 | 11.68 | 4.15 |
| Quick Ratio | 9.39 | 9.39 | 14.92 | 15.65 | 14.02 | 15.69 | 16.88 | 4.05 | 11.68 | 4.15 |
| Cash Ratio | 9.15 | 9.15 | 14.58 | 15.21 | 13.58 | 15.17 | 16.53 | 3.83 | 11.39 | 4.04 |
| Asset Turnover | — | 0.15 | 0.00 | 0.06 | 0.01 | 0.05 | 0.05 | 0.12 | 0.15 | 0.21 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | 81.66 | 0.95 | 39.85 | 51.10 | 29.03 | 20.24 |
FDMT Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
4D Molecular Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $58M | $54M | $39M | $32M | $28M | $27M | $26M | $13M | $15M |
Peer Comparison
Compare FDMT with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 FDMTYou | $519M | -4.1 | — | — | 91.1% | -187.2% | -27.6% | -28.1% | — |
 OCGN | $487M | -6.3 | — | — | 45.9% | -1425.7% | -776.9% | -1565.6% | — |
 KRYS | $9B | 43.4 | 49.2 | 46.3 | 92.6% | 41.5% | 18.9% | 18.0% | 0.1 |
 RCKT | $398M | -1.8 | — | — | — | — | -60.3% | -63.2% | — |
 QURE | $1B | -7.0 | — | — | 89.5% | -1166.8% | -207.1% | -50.7% | — |
 EDIT | $297M | -1.7 | — | — | — | — | -198.1% | — | — |
 NTLA | $2B | -3.6 | — | — | 76.5% | -651.7% | -53.5% | -44.0% | — |
 BEAM | $3B | -38.9 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 CRSP | $5B | -8.1 | — | — | -6537.0% | -16191.4% | -30.2% | -22.3% | — |
 PRME | $562M | -2.3 | — | — | -58.1% | -4498.1% | -146.8% | -168.3% | — |
 ARWR | $11B | -6389.3 | 90.4 | 69.6 | 97.1% | 11.9% | -0.5% | 9.3% | 3.0 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 9 years · Updated daily
See FDMT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs FDMT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare FDMT vs OCGN
Side-by-side business, growth, and profitability comparison vs Ocugen, Inc..
Start ComparisonFDMT — Frequently Asked Questions
Quick answers to the most common questions about buying FDMT stock.
What is 4D Molecular Therapeutics, Inc.'s P/E ratio?
4D Molecular Therapeutics, Inc.'s current P/E ratio is -4.1x. This places it at the 50th percentile of its historical range.
What is 4D Molecular Therapeutics, Inc.'s ROE?
4D Molecular Therapeutics, Inc.'s return on equity (ROE) is -27.6%. The historical average is -38.3%.
Is FDMT stock overvalued?
Based on historical data, 4D Molecular Therapeutics, Inc. is trading at a P/E of -4.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are 4D Molecular Therapeutics, Inc.'s profit margins?
4D Molecular Therapeutics, Inc. has 91.1% gross margin and -187.2% operating margin.